LATEST NEWS FROM PSYROS
PSYROS GRANTED SBRI HEALTHCARE PHASE 1 DEVELOPMENT AWARD
Psyros Diagnostics, which is developing ultra-sensitive, ultra-fast, point of care diagnostics based on single molecule counting, has been awarded a £99,400 grant by NHSEI SBRI Healthcare1 to advance their novel test for the heart attack marker troponin. Psyros’ test has significant potential to overcome the challenges associated with current troponin testing regimes in patients with suspected heart attacks, such as insufficient speed and poor logistics. The company’s proprietary technology has promise in other indications where rapid and sensitive diagnosis is crucial, such as traumatic brain injury and infectious disease, and is raising a £2.5m seed round to develop the technology further.
PSYROS RELOCATE TO DISCOVERY PARK
Psyros are pleased to announce they have relocated to Discovery Park, Kent, UK. We chose Discovery Park as it offers us excellent laboratory and office space with the opportunity to easily expand as we grow. Add to that, it is also home to a thriving and growing community of science-based businesses so is an excellent location to tap into this network. Psyros are looking forward to continuing their development journey at Discovery Park
PSYROS DIAGNOSTICS LTD. AWARDED INNOVATE UK SMART AWARD TO ACCELERATE DEVELOPMENT OF THEIR GROUND-BREAKING ULTRA-SENSITIVE IVD TECHNOLOGY
Coronary heart disease is one of the leading causes of death within the UK. Every day over 2500 patients present at A&E departments across the UK with chest pain, indicative of a suspected heart attack. Of these, only 20% will have a confirmed heart attack. Diagnosis often takes several hours after arriving at A&E while healthcare professionals wait for test results to be processed by the hospital laboratory. Faster identification of these patients will save lives and improve the outcomes for patients, ensuring they receive rapid treatment. Timely discharge of the remaining 80%, who are not suffering a heart attack, minimises unnecessary hospital admissions and costs to the NHS.
During a heart attack, a protein called troponin (Tn) is released into the bloodstream from the damaged heart muscle. Psyros are developing a game-changing point-of-care technology able to measure the extremely low levels of Tn needed by clinicians to make critical rule in/rule out care decisions as quickly as possible. Our highly innovative and patent-pending system is designed to detect these ultra-low Tn levels from a small drop of blood taken from the finger by measuring the individual Tn molecules, giving accurate and actionable results within 10 mins. We have already shown feasibility of our disruptive approach through our successful Innovate UK precision medicine feasibility award project. This project builds on the success of that feasibility work by demonstrating the required functional clinical performance.
NEIL BUTLER JOINS THE PSYROS TEAM
Neil Butler has joined Psyros, adding his wealth of experience to the team in a business development capacity.
Neil has held several senior positions within the IVD industry over the last 20 years including founding CEO of several POC IVD companies (Vivacta and Oxford Biosensors), building the business case and raising venture investment. More recently, Neil has held senior board positions for Atlas Genetics (now Binx Health), Genomic Vision, Radisens, Spectromics, QuantuMDx, Nidor in addition to running his own advisory business. We would like to take this opportunity to welcome Neil to the team!
PSYROS FILE PATENT ON IP GENERATED DURING INNOVATE UK PRECISION MEDICINE PROJECT
On the back of our successful Innovate UK project, we have filed an initial patent protecting our core IP for game-changing ultra-sensitive biological assays. Significant IP was generated during the project and further patents are anticipated in due course.
PSYROS SUCCESSFULLY COMPLETE INNOVATE UK PRECISION MEDICINE PROJECT FOR NEXT GENERATION DIAGNOSTICS
Psyros have successfully completed their Innovate UK feasibility project, demonstrating their game changing detection methodology with exquisite analytical performance for next generation IVDs with particular focus on point-of-care applications. All deliverables were met and project expectations exceeded. Psyros now intend to move to the next phase and proceed with full system development.
PSYROS AWARDED INNOVATE UK AWARD
Psyros awarded Innovate UK Precision Medicine Feasibility award to develop next generation diagnostics
We now live in an age where personalised precision medicine is a reality for many patients, enabling better health outcomes. This personalisation requires access to appropriate diagnostic tools to select the right patients for the right treatment at the right time. Whilst a large number of disease markers are detectable using existing diagnostic tools for patient selection, there are still a significant number of disease areas which have eluded suitable testing in the clinical setting due to limited sensitivity of the tests. A few examples include circulating tumour markers, Cytokines, Alzheimer's disease markers, cardiac markers, infectious disease markers.
Psyros Diagnostics is a new start-up established by a highly experienced team, with a proven track record in point-of-care clinical diagnostics. The team recognise the unmet need of ultra-sensitive testing for precision medicine.
In this project, we intend to prove the feasibility of a ground-breaking new concept for ultra-sensitive detection for use in diagnostics. When fully developed, this will open up opportunities for precision medicine for diseases where this is not currently possible, thereby improving the outcomes for patients and ultimately improving the quality of their lives.
PSYROS ACQUIRE NIJI™ SYSTEM FROM NOVARTIS
Psyros have acquired intellectual property and equipment from Novartis relating to the Niji™ point-of-care diagnostics platform. The platform consists of a dedicated reader and disposable test cartridges that are used to measure the levels of proteins, small molecules and other biomarkers in whole blood samples.
The technology is based upon a pyroelectric sensor that detects the binding of carbon in a quantitative fashion. The technology was originally developed by Vivacta and subsequently taken to CE mark by Novartis.